Riskpilot← Back to searchSign inGet full accessNordic Biotech Group Oy
OYActiveY-tunnus 2783362-7Iso Roobertinkatu 2125Manufacture of soap and detergents, cleaning and polishing preparations · NACE 2041Est. 2016— employeeswww.nordshield.com
Revenue 2024
EUR 106K
+149% vs 2023
EBITDA margin
-1817.2%
+12% vs 2023
Equity ratio
45.9%
Financial strength
Net profit 2024
EUR -2,1M
+15% vs 2023
| Revenue | EUR 106K | +149% |
| EBITDA | EUR -1,9M | +12% |
| Net profit | EUR -2,1M | +15% |
| Total assets | EUR 1,3M | +3% |
| Equity | EUR 599K | +93% |
| Employees | — | — |
Legal name
Nordic Biotech Group Oy
Y-tunnus number
2783362-7
Legal form
Osakeyhtiö
NACE code
2041 · Manufacture of soap and detergents, cleaning and polishing preparations
Founded
22. syyskuuta 2016
Share capital
EUR 2 500
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on bioteknologian alaan kuuluvien tuotteiden kehitys, valmistus ja markkinointi. Yhtiö voi omistaa ja hallita kiinteistöjä ja arvopapereita sekä harjoittaa kauppaa arvopapereilla. Tämän lisäksi yhtiön toimialaan voi kuulua kaikki muu laillinen liiketoiminta.
Address
Iso Roobertinkatu 2125
Website
www.nordshield.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 127 | 29 | 5 | 43 | 106 |
| Staff expenses | −740 | −778 | −1 249 | −934 | −873 |
| EBITDA | −1 715 | −1 660 | −2 481 | −2 193 | −1 934 |
| Depreciation & amort. | −63 | −152 | −131 | −146 | −138 |
| EBIT | −1 778 | −1 811 | −2 612 | −2 338 | −2 071 |
| Net financials | −11 | −185 | −38 | −108 | −16 |
| Profit before tax | −1 789 | −1 996 | −2 650 | −2 446 | −2 087 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −1 789 | −1 996 | −2 650 | −2 446 | −2 087 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 249 | 3 643 | 1 072 | 1 267 | 1 306 |
| Equity | 505 | 2 719 | 69 | 311 | 599 |
| Long-term debt | 456 | 473 | 421 | 336 | 390 |
| Short-term debt | 289 | 451 | 582 | 620 | 317 |
| Total debt | 744 | 924 | 1 003 | 956 | 707 |
EBITDA margin
-1817.2%
This company
15.8%
Market median
-11601% vs market
20202024
Equity ratio
45.9%
This company
38.2%
Market median
+20% vs market
20202024
Return on equity
-348.4%
This company
18.4%
Market median
-1993% vs market
20202024
Net profit margin
-1961.7%
This company
8.1%
Market median
-24319% vs market
20202024
Asset turnover
0.08×
This company
1.12×
Market median
-93% vs market
20202024
Debt / equity
1.18×
This company
0.62×
Market median
-90% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PI Chief Executive Officer | Chief Executive Officer | 2024 |
| Former (3) | ||
JK | Audit | 2017 – 2022 |
| Audit | 2022 – 2023 | |
RP Chief Executive Officer | Chief Executive Officer | 2017 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Chairperson | 2017 | |
| Board of Directors | 2024 | |
| Board of Directors | 2019 | |
| Board of Directors | 2024 | |
| Board of Directors | 2024 | |
| Former (4) | ||
| Board of Directors | 2017 – 2019 | |
| Board of Directors | 2017 – 2020 | |
| Board of Directors | 2017 – 2025 | |
| Board of Directors | 2023 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Nordic Biotech Group Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Joakim Kristoffer Rehn | Audit | 0 companies |
| Paul Ivar Wasastjerna | Chief Executive Officer | 0 companies |
| Valtteri Matti Eemeli Helenius | Audit | 0 companies |
| Rasmus Petrick Kristoffer Ekman | Chief Executive Officer | 0 companies |
| Claus Christian Ramm-Schmidt | Chairperson | 0 companies |
| Juha Eino Kullervo Mäkitalo | Board of Directors | 0 companies |
| Üllar Heinsoo | Board of Directors | 0 companies |
| Gustaf Johan Ricardo Björnberg | Board of Directors | 0 companies |
| Noelene Frances Hosking | Board of Directors | 0 companies |
| Kari Tapio Holopainen | Board of Directors | 0 companies |
| Edmund Martin Kössler | Board of Directors | 0 companies |
| Juha Matti Helenius | Board of Directors | 0 companies |
| Sami Sebastian Kalliola | Board of Directors | 0 companies |